GRP
LCTX icon

Global Retirement Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Global Retirement Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83K Buy
+1,400
New +$1.94K ﹤0.01% 4061
2025
Q4 		$2.34K Hold
1,400
– – ﹤0.01% 3678
2025
Q3 		$2.37K Hold
1,400
– – ﹤0.01% 3266
2025
Q2 		$1.27K Buy
+1,400
New +$830 ﹤0.01% 3384
2021
Q3 		– Sell
-9
Closed – – 2031
2021
Q2 		$0 Hold
9
– – ﹤0.01% 1901
2021
Q1 		$0 Hold
9
– – ﹤0.01% 1836
2020
Q4 		$0 Hold
9
– – ﹤0.01% 1773
2020
Q3 		$0 Hold
9
– – ﹤0.01% 1677
2020
Q2 		$0 Hold
9
– – ﹤0.01% 1676
2020
Q1 		$0 Hold
9
– – ﹤0.01% 1641
2019
Q4 		$0 Hold
9
– – ﹤0.01% 1668
2019
Q3 		$0 Buy
+9
New +$9 ﹤0.01% 1650

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Global Retirement Partners's LCTX Position: Q2 2026 in Review

Global Retirement Partners opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 1,400 shares worth $1.83K. The stake represents ﹤0.01% of the portfolio and ranks #4061 among its holdings. This is a return to the name: Global Retirement Partners previously reported a position in LCTX as recently as Q4 2025.

Global Retirement Partners first reported a position in LCTX in Q3 2019 and has held it in 12 quarters since. The position peaked at $2.37K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Global Retirement Partners held 1,400 shares of Lineage Cell Therapeutics worth $1.83K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Global Retirement Partners position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Global Retirement Partners's portfolio in Q2 2026, its #4061 holding.
  • Global Retirement Partners first reported a position in Lineage Cell Therapeutics in Q3 2019 and has held it in 12 quarters since.
  • Global Retirement Partners's Lineage Cell Therapeutics position peaked at $2.37K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Global Retirement Partners's 13F filing for Q2 2026, filed 6 Aug 2026.